Investor Presentaiton

Transformational transaction enabled by Royalty Pharma . morphosys Antibody research capabilities Expertise in biologics Marketed product MONJUVÍ. + Constellation PHARMACEUTICALS Epigenetics and small molecule discovery platforms 2 attractive heme candidates Accelerates growth strategy with "Pipeline-in-a-product" candidates Bolster position in hematology-oncology and entry into solid tumors Complementary capabilities strengthen research & technology organization Royalty Pharma provided up to ~$2 billion to fund the acquisition of Constellation by MorphoSys in June 2021 ROYALTY PHARMA 76

View entire presentation